The term "Artificial Pancreas Device System" refers to a continuous glucose monitor (CGM) that monitors blood sugar levels and automatically modifies insulin delivery to reduce high blood sugar levels (hyperglycemia) and reduce the likelihood of low blood sugar (hypoglycemia) with little to no input from the patient. An artificial pancreas is a three-part device that mimics how a normal pancreas regulates blood glucose, often known as blood sugar, in the body. People with type 1 diabetes typically benefit from an artificial pancreas a condition in which the pancreas does not make insulin.Artificial Pancreas Device Systems Market was valued at US$ 278.1 Million in 2024 and is projected to grow at a CAGR of 17.40% to reach US$ 1361.5 Million by 2034.

The market's expansion has been spurred by major corporations increasing investments in the artificial pancreas system. Further, rise in diabetes prevalence due to urbanization and a shift in lifestyle, ageing demographics and decline in physical activity. An increase in demand for computerized glycemic control systems may promote the target market's growth. The market can expand as a result of technological advancements that allow for the same technology to treat new chronic diseases. The introduction of new products and corporate mergers and acquisitions are anticipated to increase demand for Global Artificial Pancreas Device Systems Market expansion in the upcoming years.

The report “Artificial Pancreas Device Systems Market, By Type (Control to Range, Control to Target, and Threshold-Suspended Device Systems) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

 Key Highlights:

• In September 2022, a recent multicenter clinical trial has discovered that the bionic pancreas is better to conventional insulin delivery systems in controlling type 1 diabetes. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) provided the majority of the funding for the clinical trial.
• In November 2021, Defymed plans to include cancer and hemophilia in the bio-artificial pancreas' expanded list of potential uses. To expand the use of this artificial pancreas to treat other chronic illnesses, Defymed reported the formation of a consortium to work on an invasive version of the “Mailpan” device.
• In May 2023, The FDA (Food and Drug Administration) has given approval to “Beta Bionics'” insulin pump and automated dosing software to create artificial pancreas. The insulin pump and automated dosing software are intended to connect to a Dexcom G6 CGM to create what is known as a hybrid closed-loop system, analyzing blood sugar readings from the CGM to automatically adjust the doses delivered by the insulin pump.

Analyst View:

Increased demand for medical equipment as a result of rising diabetes incidence due to factors like physical inactivity and changing lifestyles is the main factor propelling the growth of the Artificial Pancreas Device Systems Market. The development of device to treat a variety of diseases using the same technology can help the industry grow. Because of the rise in demand for automated systems, the introduction of a computerized Artificial Pancreatic Device System may have a significant impact. Investments and acquisitions made by larger companies looking to diversify their company portfolio may increase market competitiveness and lead to Artificial Pancreas Device System’s potential market growth

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Artificial Pancreas Device Systems Market, By Type (Control to Range, Control to Target, and Threshold-Suspended Device Systems) and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Artificial Pancreas Device Systems Market was valued at US$ 278.1 Million in 2024 and is projected to grow at a CAGR of 17.40% to reach US$ 1361.5 Million by 2034.. The Global Artificial Pancreas Device Systems Market is segmented based on Type and Region.

• Based on Type, Global Artificial Pancreas Device Systems Market is segmented into Control to Range, Control to Target, and Threshold-Suspended Device Systems
• By Region, the Global Artificial Pancreas Device Systems Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Global Artificial Pancreas Device Systems Market:

The prominent players operating in the Global Artificial Pancreas Device Systems Market includes, Defymed SAS, TypeZero Technologies, Inc., Insulet Corporation, Bigfoot Biomedical, Inc., Medtronic Plc, Dexcom, Inc., Admetsys Corp., Beta Bionics, Inc., Cellnovo Group SA, and Tandem Diabetes Care, Inc.

To know more

Contact Us:

Sales

Prophecy Market Insights

U.S: 1 860 531 2574

RoW: 91 7775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com